{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:13:57Z","timestamp":1740140037889,"version":"3.37.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-024-02832-8","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T22:01:17Z","timestamp":1715810477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Accelerative Solid-State Oxidation Behaviour of Amorphous and Partially Crystalline Venetoclax"],"prefix":"10.1208","volume":"25","author":[{"given":"Jes\u00fas Alberto","family":"Afonso Urich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria","family":"Marko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Werner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Zangger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isha","family":"Saraf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrit","family":"Paudel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0636-6674","authenticated-orcid":false,"given":"Varun","family":"Kushwah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2832_CR1","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jpha.2013.09.003","volume":"4","author":"M Blessy","year":"2014","unstructured":"Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs - A review. J Pharm Anal. 2014;4:159\u201365.","journal-title":"J Pharm Anal"},{"key":"2832_CR2","doi-asserted-by":"crossref","unstructured":"Singh S, Junwal M, Modhe G, Tiwari H, Kurmi M, Parashar N, et al. Forced degradation studies to assess the stability of drugs and products. TrAC Trends Anal Chem. 2013;49:71\u201388.","DOI":"10.1016\/j.trac.2013.05.006"},{"key":"2832_CR3","unstructured":"International Council of Harmonization. Q 1 A (R2) Stability Testing of new Drug Substances and Products | Enhanced Reader."},{"key":"2832_CR4","unstructured":"International Council of Harmonization. ICH Q1B Photostability Testing of New Active Substances and Medicinal Products. 1998."},{"key":"2832_CR5","doi-asserted-by":"crossref","unstructured":"Ali MA, Hemingway R, Ott MA (2018) In Silico Drug Degradation Prediction. In: Bajaj S, Singh S (eds) Methods for stability testing of pharmaceuticals. Methods in Pharmacology and Toxicology. Humana Press, New York, NY","DOI":"10.1007\/978-1-4939-7686-7_3"},{"key":"2832_CR6","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1021\/mp5003976","volume":"11","author":"MH Kleinman","year":"2014","unstructured":"Kleinman MH, Baertschi SW, Alsante KM, Reid DL, Mowery MD, Shimanovich R, et al. In Silico Prediction of Pharmaceutical Degradation Pathways: A Benchmarking Study. Mol Pharm. 2014;11:4179\u201388.","journal-title":"Mol Pharm"},{"key":"2832_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.theochem.2010.03.032","volume":"954","author":"J Kieffer","year":"2010","unstructured":"Kieffer J, Br\u00e9mond \u00c9, Lienard P, Boccardi G. In silico assessment of drug substances chemical stability. J Mol Struct THEOCHEM. 2010;954:75\u20139.","journal-title":"J Mol Struct THEOCHEM"},{"key":"2832_CR8","doi-asserted-by":"crossref","unstructured":"Gressl C, Brunsteiner M, Davis A, Landis M, Pencheva K, Scrivens G, et al. Drug-excipient interactions in the solid state: the role of different stress factors. Mol Pharm. 2017;14:4560\u201371.","DOI":"10.1021\/acs.molpharmaceut.7b00677"},{"key":"2832_CR9","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1016\/j.xphs.2023.03.020","volume":"112","author":"J Iyer","year":"2023","unstructured":"Iyer J, Morgan LM, Harrison P, Davis A, Ray A, Mitsche S, et al. Applying material science principles to chemical stability: modelling solid state autoxidation in mifepristone containing different degrees of crystal disorder. J Pharm Sci. 2023;112:2463\u201382.","journal-title":"J Pharm Sci"},{"key":"2832_CR10","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/pharmaceutics15030848","volume":"15","author":"J Iyer","year":"2023","unstructured":"Iyer J, Karn A, Brunsteiner M, Ray A, Davis A, Saraf I, et al. Screening autoxidation propensities of drugs in the solid-state using PVP and in the solution state using N-Methyl pyrrolidone. Pharmaceutics. 2023;15:848.","journal-title":"Pharmaceutics"},{"key":"2832_CR11","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1021\/acs.molpharmaceut.2c00967","volume":"20","author":"J Iyer","year":"2023","unstructured":"Iyer J, Brunsteiner M, Ray A, Davis A, Saraf I, Paudel A. Theoretical and experimental investigation of autoxidation propensity of selected drugs in solution state. Mol Pharm. 2023;20:1768\u201378.","journal-title":"Mol Pharm"},{"key":"2832_CR12","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.3390\/pharmaceutics14061114","volume":"14","author":"J Iyer","year":"2022","unstructured":"Iyer J, Saraf I, Ray A, Brunsteiner M, Paudel A. Assessment of diverse solid\u2212 state accelerated autoxidation methods for droperidol. Pharmaceutics. 2022;14:1114.","journal-title":"Pharmaceutics"},{"key":"2832_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.jscs.2020.04.003","volume":"24","author":"W Guo","year":"2020","unstructured":"Guo W, Li C, Du P, Wang Y, Zhao S, Wang J, et al. Thermal properties of drug polymorphs: A case study with felodipine form I and form IV. J Saudi Chem Soc. 2020;24:474\u201383.","journal-title":"J Saudi Chem Soc"},{"key":"2832_CR14","doi-asserted-by":"publisher","first-page":"178353","DOI":"10.1016\/j.tca.2019.178353","volume":"680","author":"ACS Carvalho","year":"2019","unstructured":"Carvalho ACS, Zangaro GAC, Fernandes RP, Ekawa B, Nascimento ALCS, Silva BF, et al. Lornoxicam drug\u2014A new study of thermal degradation under oxidative and pyrolysis conditions using the thermoanalytical techniques, DRX and LC-MS\/MS. Thermochim Acta. 2019;680:178353.","journal-title":"Thermochim Acta"},{"key":"2832_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1208\/s12249-012-9916-y","volume":"14","author":"M Shamsipur","year":"2013","unstructured":"Shamsipur M, Pourmortazavi SM, Beigi AAM, Heydari R, Khatibi M. Thermal stability and decomposition kinetic studies of acyclovir and zidovudine drug compounds. AAPS PharmSciTech. 2013;14:287\u201393.","journal-title":"AAPS PharmSciTech"},{"key":"2832_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/1520-6017(200103)90:3<253::AID-JPS1>3.0.CO;2-W","volume":"90","author":"SW Hovorka","year":"2001","unstructured":"Hovorka SW, Sch\u00f6neich C. Oxidative degradation of pharmaceuticals: Theory, mechanisms and inhibition. J Pharm Sci. 2001;90:253\u201369.","journal-title":"J Pharm Sci"},{"key":"2832_CR17","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1002\/jps.22580","volume":"100","author":"DA Zhu","year":"2011","unstructured":"Zhu DA, Zhang GGZ, George KLST, Zhou D. A Novel Accelerated Oxidative Stability Screening Method for Pharmaceutical Solids. J Pharm Sci. 2011;100:3529\u201338.","journal-title":"J Pharm Sci"},{"key":"2832_CR18","unstructured":"World Health Organization. Technical Report Series 929 WHO Expert Committee on Specifications for Pharmaceutical Preparations. 2005."},{"key":"2832_CR19","unstructured":"United States Pharmacopoeia U-N. \u23292\u232a Oral Drug Products\u2014Product Quality Tests. 2021."},{"key":"2832_CR20","doi-asserted-by":"crossref","unstructured":"Modhave D, Barrios B, Paudel A. Pvp-h2o2 complex as a new stressor for the accelerated oxidation study of pharmaceutical solids. Pharmaceutics. 2019;11:457.","DOI":"10.3390\/pharmaceutics11090457"},{"key":"2832_CR21","unstructured":"VENCLEXTA\u00ae (venetoclax tablets): CLL\/SLL and AML Treatment."},{"key":"2832_CR22","unstructured":"Search of: venetoclax - List Results - ClinicalTrials.gov."},{"key":"2832_CR23","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","volume":"61","author":"C Lachowiez","year":"2020","unstructured":"Lachowiez C, DiNardo CD, Konopleva M. Venetoclax in acute myeloid leukemia\u2013current and future directions. Leuk Lymphoma. 2020;61:1313\u201322.","journal-title":"Leuk Lymphoma"},{"key":"2832_CR24","doi-asserted-by":"publisher","first-page":"17726","DOI":"10.1021\/acsomega.0c02338","volume":"5","author":"N \u017digart","year":"2020","unstructured":"\u017digart N, \u010casar Z. Development of a Stability-Indicating Analytical Method for Determination of Venetoclax Using AQbD Principles. ACS Omega. 2020;5:17726\u201342.","journal-title":"ACS Omega"},{"key":"2832_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics12070639","volume":"12","author":"N \u017digart","year":"2020","unstructured":"\u017digart N, \u010crnugelj M, Ila\u0161 J, \u010casar Z. On the stability and degradation pathways of venetoclax under stress conditions. Pharmaceutics. 2020;12:1\u201319.","journal-title":"Pharmaceutics"},{"key":"2832_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.hoc.2019.10.005","volume":"34","author":"JS Garcia","year":"2020","unstructured":"Garcia JS. Prospects for Venetoclax in Myelodysplastic Syndromes. Hematol Oncol Clin North Am. 2020;34:441\u20138.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2832_CR27","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1021\/ja01851a007","volume":"63","author":"C-S Lu","year":"1941","unstructured":"Lu C-S, Hughes EW, Gigu\u00e8re PA. The Crystal Structure of the Urea\u2014Hydrogen Peroxide Addition Compound CO (NH2) 2\u00b7 H2O2. J Am Chem Soc. 1941;63:1507\u201313.","journal-title":"J Am Chem Soc"},{"key":"2832_CR28","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1039\/D1CC06047C","volume":"58","author":"LI Chambers","year":"2022","unstructured":"Chambers LI, Yufit DS, Fox MA, Musa OM, Steed JW. Structure and hydration of polyvinylpyrrolidone\u2013hydrogen peroxide. Chem Commun. 2022;58:80\u20133.","journal-title":"Chem Commun"},{"key":"2832_CR29","doi-asserted-by":"crossref","unstructured":"Baertschi SW, Alsante KM. Stress testing: the chemistry of drug degradation. Pharm Stress Test. CRC Press,  Boca Raton, Florida, United States; 2016:61\u2013153.","DOI":"10.3109\/9781439801802-7"},{"key":"2832_CR30","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1021\/jp972611s","volume":"102","author":"JA Dobado","year":"1998","unstructured":"Dobado JA, Molina J, Portal D. Theoretical study on the urea\u2212 hydrogen peroxide 1: 1 complexes. J Phys Chem A. 1998;102:778\u201384.","journal-title":"J Phys Chem A"},{"key":"2832_CR31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/prep.201600101","volume":"42","author":"R Maty\u00e1\u0161","year":"2017","unstructured":"Maty\u00e1\u0161 R, Selesovsky J, Pelik\u00e1n V, Szala M, Cudzi\u0142o S, Trzci\u0144ski WA, et al. Explosive Properties and Thermal Stability of Urea-Hydrogen Peroxide Adduct. Propellants Explos Pyrotech. 2017;42:198\u2013203.","journal-title":"Propellants Explos Pyrotech"},{"key":"2832_CR32","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.3390\/pharmaceutics14122617","volume":"14","author":"O Zupan\u010di\u010d","year":"2022","unstructured":"Zupan\u010di\u010d O, Do\u011fan A, Mati\u0107 J, Kushwah V, Alva C, Spoerk M, et al. SEDEX\u2014Self-Emulsifying Delivery Via Hot Melt Extrusion: A Continuous Pilot-Scale Feasibility Study. Pharmaceutics. 2022;14:2617.","journal-title":"Pharmaceutics"},{"key":"2832_CR33","doi-asserted-by":"crossref","unstructured":"Pokar D, Sahu AK, Sengupta P. LC-Q-TOF-MS driven identification of potential degradation impurities of venetoclax, mechanistic explanation on degradation pathway and establishment of a quantitative analytical assay method. J Anal Sci Technol. 2020;11:54.","DOI":"10.1186\/s40543-020-00252-4"},{"key":"2832_CR34","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/dmd.116.071613","volume":"45","author":"H Liu","year":"2017","unstructured":"Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, et al. Metabolism and disposition of a novel b-Cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites. Drug Metab Dispos. 2017;45:294\u2013305.","journal-title":"Drug Metab Dispos"},{"key":"2832_CR35","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1080\/17460441.2022.2103535","volume":"17","author":"MN Romanelli","year":"2022","unstructured":"Romanelli MN, Manetti D, Braconi L, Dei S, Gabellini A, Teodori E. The piperazine scaffold for novel drug discovery efforts: The evidence to date. Expert Opin Drug Discov. 2022;17:969\u201384.","journal-title":"Expert Opin Drug Discov"},{"key":"2832_CR36","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1002\/jps.21767","volume":"98","author":"SA Hailu","year":"2009","unstructured":"Hailu SA, Bogner RH. Effect of the pH grade of silicates on chemical stability of coground amorphous quinapril hydrochloride and its stabilization using pH-modifiers. J Pharm Sci. 2009;98:3358\u201372.","journal-title":"J Pharm Sci"},{"key":"2832_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1002\/jps.23440","volume":"102","author":"S Ohtake","year":"2013","unstructured":"Ohtake S, Shalaev E. Effect of Water on the Chemical Stability of Amorphous Pharmaceuticals: I. Small Molecules. J Pharm Sci. 2013;102:1139\u201354.","journal-title":"J Pharm Sci"},{"key":"2832_CR38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1208\/s12249-012-9801-8","volume":"13","author":"NS Trasi","year":"2012","unstructured":"Trasi NS, Byrn SR. Mechanically induced amorphization of drugs: a study of the thermal behavior of cryomilled compounds. AAPS PharmSciTech. 2012;13:772\u201384.","journal-title":"AAPS PharmSciTech"},{"key":"2832_CR39","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1021\/acs.molpharmaceut.0c00645","volume":"18","author":"NJ Koehl","year":"2021","unstructured":"Koehl NJ, Henze LJ, Bennett-Lenane H, Faisal W, Price DJ, Holm R, et al. In silico, in vitro, and in vivo evaluation of precipitation inhibitors in supersaturated lipid-based formulations of venetoclax. Mol Pharm. 2021;18:2174\u201388.","journal-title":"Mol Pharm"},{"key":"2832_CR40","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acs.molpharmaceut.1c00678","volume":"19","author":"I Saraf","year":"2022","unstructured":"Saraf I, Roskar R, Modhave D, Brunsteiner M, Karn A, Neshchadin D, et al. Forced solid-state oxidation studies of nifedipine-PVP amorphous solid dispersion. Mol Pharm. 2022;19:568\u201383.","journal-title":"Mol Pharm"},{"key":"2832_CR41","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1134\/S1061934823040081","volume":"78","author":"V Dhiman","year":"2023","unstructured":"Dhiman V, Ahirwar S, Chaganti S, Gananadhamu S. Photolytic and oxidative degradation behavior of anticancer drug venetoclax: characterization of new degradation products using high resolution mass spectrometry. J Anal Chem. 2023;78:522\u201334.","journal-title":"J Anal Chem"},{"key":"2832_CR42","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1021\/acs.inorgchem.6b02518","volume":"56","author":"A AzhdariTehrani","year":"2017","unstructured":"AzhdariTehrani A, Esrafili L, Abedi S, Morsali A, Carlucci L, Proserpio DM, et al. Urea metal\u2013organic frameworks for nitro-substituted compounds sensing. Inorg Chem. 2017;56:1446\u201354.","journal-title":"Inorg Chem"},{"key":"2832_CR43","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1021\/cg070155j","volume":"7","author":"LS Reddy","year":"2007","unstructured":"Reddy LS, Chandran SK, George S, Babu NJ, Nangia A. Crystal structures of N-aryl-N\u2032-4-nitrophenyl ureas: molecular conformation and weak interactions direct the strong hydrogen bond synthon. Cryst Growth Des. 2007;7:2675\u201390.","journal-title":"Cryst Growth Des"},{"key":"2832_CR44","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1021\/acs.cgd.9b00269","volume":"19","author":"C Lee","year":"2019","unstructured":"Lee C, Cho AY, Yoon W, Yun H, Kang JW, Lee J. Cocrystal formation via resorcinol\u2013urea interactions: Naringenin and carbamazepine. Cryst Growth Des. 2019;19:3807\u201314.","journal-title":"Cryst Growth Des"},{"key":"2832_CR45","doi-asserted-by":"publisher","first-page":"11069","DOI":"10.1039\/C7NJ01345K","volume":"41","author":"E Khan","year":"2017","unstructured":"Khan E, Shukla A, Jadav N, Telford R, Ayala AP, Tandon P, et al. Study of molecular structure, chemical reactivity and H-bonding interactions in the cocrystal of nitrofurantoin with urea. New J Chem. 2017;41:11069\u201378.","journal-title":"New J Chem"},{"key":"2832_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1208\/s12249-023-02522-x","volume":"24","author":"J Haneef","year":"2023","unstructured":"Haneef J, Amir M, Sheikh NA, Chadha R. Mitigating drug stability challenges through cocrystallization. AAPS PharmSciTech. 2023;24:62.","journal-title":"AAPS PharmSciTech"},{"key":"2832_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1208\/s12249-021-01938-7","volume":"22","author":"H Afzal","year":"2021","unstructured":"Afzal H, Abbas N, Hussain A, Latif S, Fatima K, Arshad MS, et al. Physicomechanical, stability, and pharmacokinetic evaluation of aceclofenac dimethyl urea cocrystals. AAPS PharmSciTech. 2021;22:1\u201313.","journal-title":"AAPS PharmSciTech"},{"key":"2832_CR48","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1055\/s-2005-871968","volume":"2005","author":"S Taliansky","year":"2005","unstructured":"Taliansky S. Urea-hydrogen peroxide complex. Synlett. 2005;2005:1962\u20133.","journal-title":"Synlett"},{"key":"2832_CR49","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.xphs.2016.10.021","volume":"106","author":"DP Kale","year":"2017","unstructured":"Kale DP, Zode SS, Bansal AK. Challenges in translational development of pharmaceutical cocrystals. J Pharm Sci. 2017;106:457\u201370.","journal-title":"J Pharm Sci"},{"key":"2832_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biortech.2023.129483","volume":"386","author":"J Yang","year":"2023","unstructured":"Yang J, Wang W, Yang X, Long S, Tian X, Chen L, et al. Enhancing acidogenic fermentation of waste activated sludge via urea hydrogen peroxide pretreatment: Performance and mechanisms. Bioresour Technol. 2023;386: 129483.","journal-title":"Bioresour Technol"},{"key":"2832_CR51","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0040-6031(95)02399-M","volume":"261","author":"MC Ball","year":"1995","unstructured":"Ball MC, Massey S. The thermal decomposition of solid urea hydrogen peroxide. Thermochim Acta. 1995;261:95\u2013106.","journal-title":"Thermochim Acta"},{"key":"2832_CR52","doi-asserted-by":"crossref","unstructured":"Gabri\u010d A, Hodnik \u017d, Pajk S. Oxidation of drugs during drug product development: problems and solutions. Pharmaceutics. 2022; 14(2):325.","DOI":"10.3390\/pharmaceutics14020325"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-02832-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-024-02832-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-02832-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T16:12:50Z","timestamp":1725379970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-024-02832-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["2832"],"URL":"https:\/\/doi.org\/10.1208\/s12249-024-02832-8","relation":{},"ISSN":["1530-9932"],"issn-type":[{"type":"electronic","value":"1530-9932"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of the authors have any conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"114"}}